MPLT net incomeQ2 2026-$60.19M
MPLT net income was -$60.19M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$29.84M a year earlier. For the full fiscal 2025 it was -$161.15M, compared with -$77.58M in fiscal 2024.
MapLight Therapeutics Inc. (MPLT) financials
For the twelve months ended Jun 30, 2026, MapLight Therapeutics Inc. reported -$229.83M of net income.
- Net income, TTM
- -$229.83M
- Free cash flow, TTM
- -$175.12M
- Cash
- $71.63M
- Market cap
- $448.9M
FY2024FY2025
FY2024FY2025
MPLT revenue and earnings growth
MPLT EPSQ2 2026-$1.32
MPLT diluted EPS was -$1.32 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$18.56.
MPLT free cash flowQ2 2026-$44.89M
MPLT free cash flow was -$44.89M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$138.61M, compared with -$79.58M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $138.35M | $68.52M |
| Selling, general and admin | $30.73M | $14.42M |
| Operating income | -$169.08M | -$82.95M |
| Net income | -$161.15M | -$77.58M |
| EPS, basic | -$18.56 | -$105.38 |
| EPS, diluted | -$18.56 | -$105.38 |
| Diluted shares | 8.7M | 736,178 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $46.73M | $38.25M |
| Short-term investments | $258.37M | $70.54M |
| Current assets | $324.67M | $114.60M |
| Total assets | $479.51M | $136.92M |
| Current liabilities | $16.23M | $15.92M |
| Total liabilities | $21.14M | $21.72M |
| Shareholders' equity | $458.37M | -$193.63M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$138.14M | -$78.81M |
| Capital expenditures | $473.0K | $770.0K |
| Free cash flow | -$138.61M | -$79.58M |
| Investing cash flow | -$323.21M | -$80.79M |
| Financing cash flow | $469.82M | $118.06M |
| Stock-based compensation | $36.01M | $1.08M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $53.44M | $53.68M | $64.62M | $27.09M | $26.85M | $19.79M | $20.71M | $16.81M | - | - |
| Selling, general and admin | $10.11M | $10.82M | $18.75M | $4.40M | $3.82M | $3.76M | $2.06M | $4.08M | - | - |
| Operating income | -$63.55M | -$64.50M | -$83.38M | -$31.50M | -$30.66M | -$23.54M | -$22.78M | -$20.89M | - | - |
| Net income | -$60.19M | -$60.67M | -$79.55M | -$29.42M | -$29.84M | -$22.34M | -$21.23M | -$19.02M | -$18.40M | -$18.93M |
| EPS, basic | -$1.32 | -$1.34 | - | -$37.18 | -$39.11 | -$29.33 | - | -$25.08 | - | - |
| EPS, diluted | -$1.32 | -$1.34 | - | -$37.18 | -$39.11 | -$29.33 | - | -$25.08 | - | - |
| Diluted shares | 45.4M | 45.3M | - | 791,127 | 763,044 | 761,598 | - | 758,204 | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $71.63M | $55.71M | $46.73M | $64.15M | - | - | $38.25M | - | - | - |
| Short-term investments | $233.09M | $254.41M | $258.37M | $163.02M | - | - | $70.54M | - | - | - |
| Current assets | $318.79M | $327.23M | $324.67M | $245.31M | - | - | $114.60M | - | - | - |
| Total assets | $368.35M | $418.79M | $479.51M | $257.22M | - | - | $136.92M | - | - | - |
| Current liabilities | $19.29M | $14.28M | $16.23M | $18.56M | - | - | $15.92M | - | - | - |
| Total liabilities | $20.05M | $18.95M | $21.14M | $23.71M | - | - | $21.72M | - | - | - |
| Shareholders' equity | $348.30M | $399.83M | $458.37M | -$274.18M | -$245.06M | -$215.83M | -$193.63M | -$172.37M | -$154.33M | -$136.00M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.87M | -$51.18M | -$46.83M | -$31.79M | -$33.97M | -$25.55M | -$21.49M | - | - | - |
| Capital expenditures | $22.0K | $24.0K | $376.0K | $31.0K | - | - | $106.0K | - | - | - |
| Free cash flow | -$44.89M | -$51.20M | -$47.20M | -$31.82M | - | - | -$21.59M | - | - | - |
| Investing cash flow | $60.70M | $67.01M | -$242.55M | -$135.59M | $17.43M | $37.50M | $32.39M | - | - | - |
| Financing cash flow | $92.0K | -$6.85M | $271.96M | $198.06M | -$156.0K | -$47.0K | $5.0K | - | - | - |
| Stock-based compensation | $8.63M | $9.64M | $35.52M | $125.0K | $148.0K | $212.0K | $214.0K | - | - | - |
Key ratios
Source: XBRL data MapLight Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MPLT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MPLT | - | - | -$229.83M | - | $448.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
MPLT FAQ
5 questionsIs MPLT profitable?
No. MapLight Therapeutics Inc. reported a net loss of $229.83M for the twelve months ended Jun 30, 2026.How much cash and debt does MPLT have?
MapLight Therapeutics Inc. reported $71.63M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is MPLT free cash flow?
MapLight Therapeutics Inc. generated -$175.12M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$174.67M less capital expenditures.When did MPLT last report financial results?
The latest statements here come from MapLight Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this MPLT financial data come from?
Quantisnow builds these statements from the structured XBRL data MapLight Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.